Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BMY

BMY - Bristol-Myers Squibb Co Stock Price, Fair Value and News

$59.08+0.13 (+0.22%)
Delayed

48/100

BMY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

48/100

BMY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BMY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BMY Price Action

Last 7 days

-2.0%

Last 30 days

-1.4%

Last 90 days

12.7%

Trailing 12 Months

-2.0%

BMY RSI Chart

BMY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BMY Valuation

Market Cap

120.3B

Price/Earnings (Trailing)

17.06

Price/Sales (Trailing)

2.5

EV/EBITDA

11.62

Price/Free Cashflow

9.37

BMY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BMY Fundamentals

BMY Revenue

Revenue (TTM)

48.2B

Rev. Growth (Yr)

1.3%

Rev. Growth (Qtr)

2.29%

BMY Earnings

Earnings (TTM)

7.1B

Earnings Growth (Yr)

1.4K%

Earnings Growth (Qtr)

-50.61%

BMY Profitability

EBT Margin

19.36%

Return on Equity

38.19%

Return on Assets

7.83%

Free Cashflow Yield

10.68%

BMY Investor Care

Dividend Yield

4.21%

Dividend/Share (TTM)

2.49

Shares Dilution (1Y)

0.35%

Diluted EPS (TTM)

3.46

BMY Alerts

  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202547.6B47.7B48.0B48.2B
202445.5B46.5B47.4B48.3B
202345.8B45.2B44.9B45.0B
202247.0B47.1B46.7B46.2B
202142.8B44.4B45.5B46.4B
202031.0B34.9B39.4B42.5B
201923.3B23.9B24.2B26.1B
201821.0B21.6B22.0B22.6B
201720.0B20.2B20.6B20.8B
201616.9B17.6B18.5B19.4B
201516.1B16.4B16.5B16.6B
201416.4B16.2B16.1B15.9B
201316.2B15.8B16.1B16.4B
201221.5B20.5B18.9B17.6B
201119.7B20.4B20.9B21.2B
Get all data in R, Python etc through our Historical Stock Data APIs

About Bristol-Myers Squibb Co

BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
 CEO
 WEBSITEbms.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES34300

Bristol-Myers Squibb Co Frequently Asked Questions

BMY is the stock ticker symbol of Bristol-Myers Squibb Co. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Bristol-Myers Squibb Co is 120.31 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, BMY's PE ratio (Price to Earnings) is 17.06 and Price to Sales (PS) ratio is 2.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMY PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Bristol-Myers Squibb Co has provided -0.007 (multiply by 100 for percentage) rate of return.